Physician profile
Margaret C Boltja
NPI 1184671133
$7,166.94
in general payments reported to CMS, 2019-2025
37 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $601 · 2021: $2,134 · 2022: $1,070 · 2023: $1,330 · 2024: $873 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483 · Travel and Lodging: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.16 |
| Travel and Lodging | $232.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,317.78 | 2019-2024 | Senza |
| Abbott Laboratories | $950.18 | 2020-2023 | Proclaim |
| Spr Therapeutics, INC | $530.47 | 2022-2025 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $407.35 | 2019-2024 | Xtampza, Belbuca |
| Si-Bone, INC. | $317.55 | 2024-2025 | |
| Curonix LLC | $294.50 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Emd Serono, INC. | $253.38 | 2019-2020 | |
| Boston Scientific Corporation | $215.48 | 2019-2024 | Coyote Es, Ranger |
| Saluda Medical Americas, INC. | $194.19 | 2025 | Evoke |
| Medtronic, INC. | $190.68 | 2023 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Closurefast |
| Mml US, INC. | $158.81 | 2024 | Reactiv8 |
| Biogen, INC. | $148.65 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $126.87 | 2019-2023 | Reyvow, Emgality |
| Pfizer INC. | $121.60 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $105.83 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $91.93 | 2020-2022 | |
| Amgen INC. | $91.33 | 2019-2022 | |
| Biotronik Nro, INC. | $83.47 | 2023-2024 | Prospera, Biotronik |
| Vertos Medical, INC. | $74.49 | 2023-2024 | Mild Device Kit |
| Allergan, INC. | $67.56 | 2019 | |
| Grt US Holding, INC. | $60.00 | 2022 | |
| Scilex Pharmaceuticals INC. | $56.27 | 2022 | |
| Globus Medical, INC. | $35.55 | 2025 | Senza |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Genzyme Corporation | $34.79 | 2019 | |
| Almatica Pharma LLC | $30.49 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $21.55 | 2021 | |
| Acadia Pharmaceuticals INC | $20.21 | 2025 | Nuplazid |
| Ucb, INC. | $18.37 | 2020 | |
| Depuy Synthes Sales INC. | $18.12 | 2021 | |
| Argenx US, INC. | $17.34 | 2025 | Vyvgart Hytrulo |
| Neurelis, INC. | $14.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2019 | |
| Biodelivery Sciences International, INC. | $14.06 | 2021 | |
| Redhill Biopharma INC. | $13.81 | 2020 | |
| Zimmer Biomet Holdings, INC. | $11.39 | 2019 | |
| Foundation Fusion Solutions, LLC | $8.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Boltja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.